Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Public ClinicalTrials.gov record NCT05396105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Study identification
- NCT ID
- NCT05396105
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Conditions
- C1 Esterase Inhibitor Deficiency
- C1 Esterase Inhibitor [C1-INH] Deficiency
- C1 Esterase Inhibitor, Deficiency of
- C1 Inhibitor Deficiency
- Hereditary Angioedema
- Hereditary Angioedema (HAE)
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- Hereditary Angioedema - Type 3
- Hereditary Angioedema Attack
- Hereditary Angioedema Type I
- Hereditary Angioedema Type I and II
- Hereditary Angioedema Type II
- Hereditary Angioedema Type III
- Hereditary Angioedema Types I and II
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
Interventions
- deucrictibant Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2022
- Primary completion
- May 31, 2027
- Completion
- May 31, 2027
- Last update posted
- Mar 15, 2026
2022 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study site | Birmingham | Alabama | 35209 | — |
| Study site | Scottsdale | Arizona | 85258 | — |
| Study site | Little Rock | Arkansas | 72205 | — |
| Study site | San Diego | California | 92122 | — |
| Study site | Santa Monica | California | 90404 | — |
| Study site | Walnut Creek | California | 94598 | — |
| Study site | Colorado Springs | Colorado | 80907 | — |
| Study site | Chevy Chase | Maryland | 20815 | — |
| Study site | Boston | Massachusetts | 02115 | — |
| Study site | Detroit | Michigan | 48202 | — |
| Study site | St Louis | Missouri | 63141 | — |
| Study site | Hershey | Pennsylvania | 17033 | — |
| Study site | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05396105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05396105 live on ClinicalTrials.gov.